European-based pharmaceutical company MGC Pharmaceuticals (ASX:MXC) reports it has completed the delivery of its ‘largest’ order of ArtemiC to AMC Holdings which is the company’s US distribution and marketing partner.
The company says the order valued at $1 million was received in October, with the product being delivered in a single shipment ready for supply, with demand increasing in the US.
AMC Holdings representative Brent W. Yessin says: “AMC are excited to bring the first commercial order of ArtemiC into the US. It will be available both online and through independent pharmacies.
Since the pandemic, the federal government has stopped paying for many treatments and the cost burden has shifted to the individual states and consumers.
“AMC are excited to bring the first commercial order of ArtemiC into the US. It will be available both online and through independent pharmacies”
With this change in policy AMC are pleased to be in a position to offer the market a natural, plant based and clinically tested treatment option.”
MGC reports delivery of this ‘large’ consignment of ArtemiC has now been completed marking the first substantial commercial delivery of the product under the AMC US supply and distribution agreement to date.
MGC Pharmaceuticals is a European-based pharmaceutical company focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies with the goal of finding or producing treatments for unmet medical conditions.
